We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
-6.84%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$23.1B
AUM Growth
-$3.48B
(-13%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TLIS
Talis Biomedical Corporation Common Stock
TLIS
|
+$126M |
| 2 |
Immunocore
IMCR
|
+$112M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$106M |
| 4 |
Instil Bio
TIL
|
+$99.9M |
| 5 |
Design Therapeutics
DSGN
|
+$48.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$737M |
| 2 |
Korro Bio
KRRO
|
+$31.1M |
| 3 |
Adaptive Biotechnologies
ADPT
|
+$22.5M |
| 4 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$13M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$11.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.81% |
| 2 | Miscellaneous | 0.19% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Intellia Therapeutics
NTLA
$1.61B
| – | – |
-111,296
| Closed | -$6.05M |
|
127
Ovid Therapeutics
OVID
$518M
| – | – |
-955,690
| Closed | -$2.21M |
|
128
uniQure
QURE
$3.06B
| – | – |
-6,740
| Closed | -$244K |
|
129
Arcus Biosciences
RCUS
$2.99B
| – | – |
-72,709
| Closed | -$1.89M |
|
|
VXRT
130
DELISTED
Vaxart
VXRT
| – | – |
-1,398,795
| Closed | -$7.99M |
|
|
VIRX
131
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-15,162
| Closed | -$106K |
|
|
INFI
132
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-522,360
| Closed | -$1.11M |
|
|
DRNA
133
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-102,121
| Closed | -$2.25M |
|
|
GWPH
134
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-112,897
| Closed | -$13M |
|
|
FPRX
135
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-668,000
| Closed | -$11.4M |
|
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Baker Bros. Advisors held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Baker Bros. Advisors's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.
- Baker Bros. Advisors's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
- Baker Bros. Advisors added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
- Baker Bros. Advisors's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
- Baker Bros. Advisors fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
- Baker Bros. Advisors's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
- Baker Bros. Advisors opened 11 new positions and closed 12 in Q1 2021.
- Baker Bros. Advisors's portfolio value fell 13% quarter-over-quarter to $23.1B.
Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.